131 related articles for article (PubMed ID: 24819973)
21. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
22. Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression.
Gobbi G; Ghabrash MF; Nuñez N; Tabaka J; Di Sante J; Saint-Laurent M; Vida S; Kolivakis T; Low N; Cervantes P; Booij L; Comai S
Int Clin Psychopharmacol; 2018 Jan; 33(1):34-43. PubMed ID: 28906325
[TBL] [Abstract][Full Text] [Related]
23. An open study of lamotrigine in refractory bipolar depression.
Kusumakar V; Yatham LN
Psychiatry Res; 1997 Sep; 72(2):145-8. PubMed ID: 9335206
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
[TBL] [Abstract][Full Text] [Related]
25. Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression.
Bowden CL; Singh V; Weisler R; Thompson P; Chang X; Quinones M; Mintz J
Acta Psychiatr Scand; 2012 Nov; 126(5):342-50. PubMed ID: 22708645
[TBL] [Abstract][Full Text] [Related]
26. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
[TBL] [Abstract][Full Text] [Related]
27. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
[TBL] [Abstract][Full Text] [Related]
28. Effect of lamotrigine on depressive symptoms in adult patients with epilepsy.
Ettinger AB; Kustra RP; Hammer AE
Epilepsy Behav; 2007 Feb; 10(1):148-54. PubMed ID: 17071141
[TBL] [Abstract][Full Text] [Related]
29. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression.
Schaffer A; Zuker P; Levitt A
J Affect Disord; 2006 Nov; 96(1-2):95-9. PubMed ID: 16820213
[TBL] [Abstract][Full Text] [Related]
30. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study.
Zarate CA; Payne JL; Singh J; Quiroz JA; Luckenbaugh DA; Denicoff KD; Charney DS; Manji HK
Biol Psychiatry; 2004 Jul; 56(1):54-60. PubMed ID: 15219473
[TBL] [Abstract][Full Text] [Related]
31. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
[TBL] [Abstract][Full Text] [Related]
32. Bipolar depression: a new role for atypical antipsychotics?
Keck PE
Bipolar Disord; 2005; 7 Suppl 4():34-40. PubMed ID: 15948765
[TBL] [Abstract][Full Text] [Related]
33. Lamotrigine as an augmentation agent in treatment-resistant depression.
Barbee JG; Jamhour NJ
J Clin Psychiatry; 2002 Aug; 63(8):737-41. PubMed ID: 12197456
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A
Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
[TBL] [Abstract][Full Text] [Related]
35. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials.
Goff DC; Keefe R; Citrome L; Davy K; Krystal JH; Large C; Thompson TR; Volavka J; Webster EL
J Clin Psychopharmacol; 2007 Dec; 27(6):582-9. PubMed ID: 18004124
[TBL] [Abstract][Full Text] [Related]
36. Brain-derived neurotrophic factor serum concentrations in acute depressive patients increase during lithium augmentation of antidepressants.
Ricken R; Adli M; Lange C; Krusche E; Stamm TJ; Gaus S; Koehler S; Nase S; Bschor T; Richter C; Steinacher B; Heinz A; Rapp MA; Borgwardt S; Hellweg R; Lang UE
J Clin Psychopharmacol; 2013 Dec; 33(6):806-9. PubMed ID: 24018547
[TBL] [Abstract][Full Text] [Related]
37. N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial.
Berk M; Copolov DL; Dean O; Lu K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Bush AI
Biol Psychiatry; 2008 Sep; 64(6):468-75. PubMed ID: 18534556
[TBL] [Abstract][Full Text] [Related]
38. Lamotrigine augmentation strategy for patients with treatment-resistant depression.
Gutierrez RL; McKercher RM; Galea J; Jamison KL
CNS Spectr; 2005 Oct; 10(10):800-5. PubMed ID: 16400242
[TBL] [Abstract][Full Text] [Related]
39. Low dosage lithium augmentation in venlafaxine resistant depression: an open-label study.
Alevizos B; Alevizos E; Leonardou A; Zervas I
Psychiatriki; 2012; 23(2):143-8. PubMed ID: 22796912
[TBL] [Abstract][Full Text] [Related]
40. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
